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Abstract
Anti-GM1 antibodies are present in some patients with autoimmune neurological disorders. These
antibodies are most frequently associated with acute immune neuropathy called Guillain-Barré
syndrome (GBS). Some clinical studies associate the presence of these antibodies with poor
recovery in GBS. The patients with incomplete recovery have failure of nerve repair, particularly
axon regeneration. Our previous work indicates that monoclonal antibodies can inhibit axon
regeneration by engaging cell surface gangliosides (Lehmann et al., 2007). We asked whether
passive transfer of human anti-GM1 antibodies from patients with GBS modulate axon
regeneration in an animal model. Human anti-GM1 antibodies were compared with other GM1
ligands, cholera toxin B subunit and a monoclonal anti-GM1 antibody. Our results show that
patient derived anti-GM1 antibodies and cholera toxin β subunit impair axon regeneration/repair
after PNS injury in mice. Comparative studies indicated that the antibody/ligand-mediated
inhibition of axon regeneration is dependent on antibody/ligand characteristics such as affinity-
avidity and fine specificity. These data indicate that circulating immune effectors such as human
autoantibodies, which are exogenous to the nervous system, can modulate axon regeneration/nerve
repair in autoimmune neurological disorders such as GBS.
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Introduction
Anti-glycolipid antibodies (Abs) of various specificities have been described in association
with several autoimmune disorders of peripheral and central nervous systems (PNS and
CNS) including immune neuropathies and multiple sclerosis (Cross et al., 2001;Willison and
Yuki, 2002). In neuroimmunological disorders autoantibodies against GM1 (a major
ganglioside of vertebrate PNS and CNS (Svennerholm et al., 1992)) are frequently reported
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(Ogawara et al., 2000;Kanter et al., 2006). Anti-GM1 Abs have strongest association with
axonal forms of Guillain-Barré syndrome (GBS) (Yuki et al., 1990;Ho et al., 1995;Hadden
et al., 1998;Ogawara et al., 2000), which is now the commonest cause of acute flaccid
paralysis worldwide. GBS comprises a group of clinically and pathophysiologically related,
acute monophasic demyelinating and axonal neuropathic disorders of autoimmune origin
(Willison and Yuki, 2002;Hughes and Cornblath, 2005). There is strong evidence for
postinfectious molecular mimicry as a mechanism for the induction of anti-ganglioside
(including anti-GM1) Abs in GBS (Yuki et al., 1992;Aspinall et al., 1994;Jacobs et al.,
1997;Sheikh et al., 1998). Some clinical studies indicate that anti-GM1 Abs in adult patient
groups with GBS are associated with poor prognosis and/or incomplete recovery (Ilyas et
al., 1992;Gregson et al., 1993;Simone et al., 1993;Kuwabara et al., 1998b;Kuwabara et al.,
1998a;Jacobs et al., 1996;Carpo et al., 1999;Bech et al., 1997;Press et al., 2001;Annunziata
et al., 2003;Koga et al., 2003). The patients with incomplete recovery almost always have
some degree of failure of nerve repair/axon regeneration and target reinnervation (Brown
and Feasby, 1984). These clinical observations raise the possibility that anti-GM1 Abs can
adversely affect the nerve repair process in this disease and potentially in other disorders
associated with anti-GM1 antibodies.
To test this hypothesis we examined the effects of IgG anti-GM1 antibodies present in
patients with axonal forms of GBS in a peripheral nerve injury and repair paradigm,
described previously (Lehmann et al., 2007). Further, as a proof of concept, we studied the
effects of two different GM1 ligands, namely, Cholera toxin β subunit (CTB) and a specific
IgG anti-GM1 monoclonal antibody (mAb) on nerve repair. Our data provide evidence that
engagement of GM1-like epitopes by autoimmune Abs could be a mechanism that impairs
axon regeneration. An implication of this finding is that circulating immune factors,
including autoAbs, can inhibit axonal regeneration/neural repair; an effect that is mostly
attributed to endogenous regeneration inhibitors in CNS.
Materials and Methods
Patient sera
Plasma from one patient with Acute Motor Sensory Axonal Neuropathy (AMSAN, JHH-9)
and one patient with Acute Motor Axonal neuropathy (AMAN, patient 98-7) with high titers
if IgG anti-GM1 Abs were collected during the acute phase of the disease from Plasma
Exchange (PE) performed as part of their treatment. Plasma was later dialyzed against PBS
to remove anticoagulants, filtered and stored at −20°C until use. Serum from a normal
healthy volunteer without reactivity against GM1 was used as negative control.
IgG fractions and affinity purified anti-GM1 Abs were prepared from the serum of patient
JHH-9. The IgG fractions from sera were prepared using a Protein G Sepharose column (GE
healthcare, Piscataway, NJ, USA) according to the manufacturer’s instructions. Anti-GM1
Abs from serum (JHH-9) were purified by affinity chromatography using GM1 ganglioside
according to the method described by Hirabayasi et al. (Hirabayashi et al., 1983). The
purified Abs were stored at −20°C until use.
GM1 ligands
For comparison to the patient derived antibodies a non-antibody GM1 ligand, i.e., cholera
toxin subunit B (CTB; List Biologicals, Campbell, CA) was used in animal studies. A
previously well characterized IgG2b monoclonal antibody (mAb) specific against GM1
(GM1-2b) was also included for passive transfer studies. The generation, specificity, and
production of this mAb were reported previously (Schnaar et al., 2002;Gong et al., 2002). In
the present study, GM1-2b mAb hollow fiber supernatant was used for animal studies.
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Sciatic nerve crush model
All studies were done on 12- to 16-week-old wild-type (C57BL/6) mice. Experimental
procedures were approved by the institutional Animal Care and Use Committee. A
standardized mouse sciatic nerve crush model was used (Lehmann et al., 2007). Sciatic
nerves were crushed 35 mm rostral to the middle toe for 30 s with fine forceps on day 0,
either on left side or bilaterally. Separation of proximal and distal endoneurial contents
indicated complete crush. Animals injected with human sera were pretreated with 100 mg/kg
cyclophosphamide intraperitonealy (i.p.) two days prior to the nerve crush to minimize the
immune response (serum sickness) to human proteins, as described (Toyka et al., 1977).
These wild type mice received daily i.p. injections of 1 ml of sera from patient JHH-9 (n =
12 nerves), patient 98–7 (n = 4 nerves), or control human sera (n = 8 nerves) for fifteen days.
Further passive transfer studies were done with the JHH-9 IgG fractions (n = 4 nerves) or
affinity purified polyclonal IgG anti-GM1 Abs (n = 4 nerves). For the studies with the
patient IgGs human intravenous immunoglobulin (IVIg) (Carimune NF, ZLB Bioplasma,
Glendale, CA) was used as control (n = 4 nerves).
The effects of JHH-9 serum were also examined on the regeneration of sensory (sural)
nerves. For these studies wild type mice were pretreated with 100 mg/kg cyclophosphamide
intraperitonealy (i.p.) two days prior to surgeries. Sural nerves were crushed 22 mm rostral
to the middle toe for 30 s with fine forceps on day 0, on left side. These animals received ten
daily i.p. injections of 1 ml of JHH-9 serum (n = 3) or healthy control serum without anti-
ganglioside reactivity (n = 3) and nerves were harvested on day 11 after crush for
morphological studies.
In another set of studies CTB or GM1-2b were administered to wild type mice. These
animals did not receive cyclophosphamide pretreatment because serum sickness was not
anticipated with these ligands. CTB or vehicle control (1 ml total volume) was administered
to mice (n = 8 nerves each) i.p., 0.5 mg on day 0 and 0.25 mg on days 3, 5, and 7 after the
crush. Another group of animals was administered five doses of GM1-2b mAb (hollow fiber
supernatant containing 2 mg/ml) or control IgG (2 mg/ ml) on days 0, 3, 5, 7, and 9 after
surgery i.p. (n = 4 nerves each).
At day 15 or 16 after surgery, a magnetic resonance imaging (MRI) of the calf muscles and/
or electrophysiology was done in a selected group of animals and mice were sacrificed on
day 16 or 17 after nerve crush and tissues and sera were harvested for morphological and
serological analysis.
Morphometry
Mice were perfused with a mixture of 3% glutaraldehyde and 4% paraformaldehyde. Sciatic
and tibial nerves were harvested and immersion-fixed overnight before processing. For
morphology, three segments of the crushed sciatic nerves were analyzed (Fig. 1A): S1, 10
mm proximal to the crush site; S2, 10 mm distal to the crush site (sciatic nerve segment) and
S3, 20mm distal to the crush site (tibial nerve segment). For sural nerve studies a segment of
the nerve 12 mm distal to the crush site was collected for analysis. These segments were
embedded in Epon, and 1μm cross sections were stained with toluidine blue as described
(Sheikh et al., 1999b;Sheikh et al., 2004). Sections from nerve segments were used for
quantification at light level (40X lens) by a motorized stage and stereotactic imaging
software (Stereo Investigator, version 5). We counted all myelinated regenerating sprouts in
a single whole cross section of the nerve. Sciatic nerve cross sections (S2) were used for
quantifying mean caliber of regenerating axons/sprouts in S2 segments as well for electron
microscopy in studies with CTB. Caliber was calculated from the diameter of a circle with
an area equivalent to that of each axon/sprout, as described previously (Sheikh et al., 2004).
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Electrophysiology
These studies were done in selected groups of animals. Sciatic nerves were stimulated at the
sciatic notch and compound muscle action potential (CMAP) amplitudes were recorded with
a PowerLab signal acquisition set-up (ADInstruments, Grand Junction, CO) in the hindpaws
as described (Lehmann et al., 2007).
Magnetic resonance imaging
Live anesthetized animals were imaged by an 11.7 Tesla nuclear magnetic resonance
spectrometer (Bruker Biospec, Billerica, MA, USA) and processed, as described (Zhang et
al., 2008). From 3D images of the leg, volumetric measurements of all muscle groups were
obtained (Lehmann et al., 2007).
Immunostaining
Sciatic nerves were harvested on day 16–17 after nerve crush and fixed with 4%
paraformaldehyde for 24 h. These nerves were cryoprotected with sucrose, longitudinally
sectioned (10μm) and immunostained with anti-human IgG γ chain specific Abs conjugated
to Cy3 (Jackson Immunoresearch laboratories) and analyzed by fluorescent microscopy, as
described (Lehmann et al., 2007).
Determination of antibody titer
The titers of circulating IgG anti-GM1 Abs in mouse sera, collected at the time of tissue
harvesting, was determined by ELISA, as described (Lopez et al., 2000).
Determination of affinity
The affinity of GBS patient sera (patients JHH-9 and 98-7) and a mAb (GM1-2b) used in
our studies were determined with soluble GM1-oligosaccharide in a soluble binding
inhibition assay, as described (Lopez et al., 2002). GM1-oligosaccharide was used as a
competing antigen because it is soluble and the values obtained can be considered as
monovalent affinity. GM1-oligosaccharides were generated as described (Lopez et al.,
2008). GM1-oligosaccharidesfrom GM1 gangliosidewere generated by a specific ceramide
glycanase (1 U/mg of ganglioside)as suggested by the manufacturer's instructions
(Calbiochem)that catalyses removal of ceramide moieties from gangliosides,and their
identity was confirmed by mass spectrometry througha core facility at Johns Hopkins
University. Different concentrations of soluble sugars (10−4 to 10−7 M) were used to
determine the amount of oligosaccharide required for 50% inhibition of Ab binding to GM1
(IC50%).
Immunostaining of ventral and dorsal roots
Affinity purified anti-GM1 antibodies from patient JHH-9 were used for these studies.
Cauda equina collected from adult 8–12-week-old Sprague-Dawley rats were snap-frozen in
isopentane at −70°C and cryosectioned. These sections were immunostained with purified
IgG anti-GM1 Abs from patient JHH-9 diluted (1/20), as described (Lopez et al., 2008).
Isolectin B4 (IB4) (Sigma, St Louis, MO, USA) was used to mark Remak bundles in
sensory roots in cauda equina, as described (Gong et al., 2002).
Preparation of GM1-derivatives
GM1-derivatives were synthesized to examine the fine specificity of different GM1 ligands
used in this study. Sialic acid on GM1 was modified to obtain GM1 NeuAc 1-amide, GM1
NeuAc 1-alcohol, GM1 NeuAc 1-methyl ester, and GM1 NeuAc 7-aldehyde, as described
previously (Lopez et al., 2008). GM1-de-N-acetyl was derived by removal of the N-acetyl
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group of GM1 sialic acid. This was achieved by incubating 2 mg of GM1 in 0.4 ml of
DMSO, 3.2 ml of water and 0.4 ml of 10M KOH at 100°C for 4 hours as described (Nores et
al., 1988). Products were analysed by thin-layer chromatography (TLC) and fast atom
bombardment-mass spectrometry (Dell et al., 1994). at the Middle Atlantic Mass
Spectrometry Laboratory.
Binding of GM1 ligands to GM1-derivatives
Binding of GM1 ligands (JHH-9, 98-7, CTB, and GM1-2b) to GM1 and GM1-derivatives
was determined by either ELISA or TLC-immunoverlay and quantified, as described (Lopez
et al., 2000;Lopez et al., 2008). These studies were repeated at least oncewith all ligands.
Statistical analysis
All numerical results are presented as mean + SEM. Differences between groups were
determined using ANOVA with corrections for multiple comparisons or student’s t test, p
values < 0.05 were considered statistically significant.
Results
Passive transfer of GBS sera containing high titers of circulating IgG anti-GM1 ganglioside
Abs impairs nerve repair in the PNS
In order to study the effect of circulating IgG anti-GM1 Abs on nerve repair, we passively
transferred sera containing high titers of these Abs in a mouse model of nerve regeneration
described previously (Lehmann et al., 2007). In this model (Fig. 1A) the distal stump
undergoing Wallerian degeneration has breakdown of blood-nerve-barrier allowing
circulating Abs to access injured nerve undergoing repair. We found that sera from GBS
patients decreased the number of regenerating axons in sciatic and tibial nerve segments (S2
and S3 segments, respectively) compared to those in controls (sham Ab-treated regenerating
nerves) (Fig. 1B&C). Morphometric analysis showed that compared to controls the numbers
of regenerating myelinated fibers (MFs) in the S2 segment were decreased by ~39% and
32% with the administration of AMSAN (JHH-9) and AMAN (98-7) sera, respectively (Fig.
1D). The inhibitory effect was more pronounced at the tibial (S3 segment) level and
numbers of MFs at this level were decreased by ~70%, 42% with the administration of
AMSAN (JHH-9) and AMAN (98-7) respectively (Fig. 1E). Nerve segments above the
crush site (S1 segments) did not show any antibody related injury (data not shown),
consistent with our previous results (Lehmann et al., 2007).
Passive transfer of IgG anti-GM1 Abs from AMSAN serum inhibits axon regeneration in the
PNS
These studies were restricted to serum from patient with AMSAN (JHH-9) because
sufficient quantities were not available to perform these studies with AMAN sera (98-7).
The goal of these studies was to directly link IgG anti-GM1 Abs with inhibition of axon
regeneration. IgG fractions were isolated by protein-G affinity chromatography and
administered to animals with sciatic nerve crush injury, as described in Materials and
Methods. We found that IgG fractions from AMSAN serum decreased the number of
regenerating MFs by ~22% and 67% in sciatic (S2) and tibial (S3) nerves, respectively (Fig.
2A&B). Further, affinity purified IgG anti-GM1 Abs from AMSAN serum decreased the
number of regenerating MFs by ~28% and 40% in sciatic (S2) and tibial (S3) nerves,
respectively (Fig. 2A&B). The inhibition induced by affinity purified IgG anti-GM1 Abs
was less than the corresponding serum and IgG fractions. This could reflect less activity of
the purified anti-GM1 Abs transferred passively due to differences in pharmacokinetics of
purified Abs versus whole serum. Alternatively, GBS serum contained inhibitory factors
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other than anti-GM1 Abs. Overall, these sequential studies directly link the inhibitory effects
on nerve repair to IgG fractions and IgG anti-GM1 Abs in the AMSAN serum.
Human IgG antibodies access injured peripheral nerves
In order to demonstrate that passively transferred human IgG circulating antibodies accessed
the injured nerve; we analyzed the presence of IgG in sciatic nerve sections by
immunocytochemistry (ICC). Figure 3 shows that immunoreactivity for human IgG was
seen in the endoneurial compartment of injured nerves in both AMSAN serum and control
IgG administered animals. Quantification showed significantly more (~40%; p < 0.05)
immunoreactivity (pixel intensity) for human IgG in nerves treated with AMSAN serum (62
± 21) compared to controls (40 ± 18). These results are consistent with our previous findings
that with nerve injury both specific and non-specific immunoglobulins are recruited to the
endoneurium but more immunoglobulins are retained in the anti-ganglioside antibody
treated nerves (Lehmann et al., 2007).
Passive transfer of AMSAN serum impairs sensory nerve regeneration
These studies were done to evaluate the effects of AMSAN serum on sensory nerve
regeneration. JHH-9-treated nerves had almost no regenerating fibers compared to control
serum treated nerves (Fig. 4A&B). Analysis of sural nerves showed a significant (p ≤ 0.05)
reduction in the regeneration of the MFs in animals treated with JHH-9 serum (1.3 ± 0.7)
compared to control serum-treated mice (52.3 ± 18.9). This finding would suggest that these
antibodies predominantly inhibit sensory fiber regeneration in mice. Our finding that
immunostaining of rodent cauda equina using affinity purified IgG anti-GM1 Abs from
AMSAN serum showed a preferential staining of sensory fibers (Figure 4C) would be
consistent with inhibition of sensory fiber regeneration.
Passive transfer of AMSAN serum does not impair motor reinnervation
We used two measures of motor reinnervation in sciatic nerve crush model, these include
sciatic nerve conductions and volumetric magnetic resonance imaging (MRI) of the calf
muscles. We found that compound motor axonal potential (CMAP) amplitudes in hindpaw
were delayed and dispersed (consistent with regeneration) in both AMSAN and control sera
treated animals (Fig. 5A) with no quantitative differences between two groups (data not
shown). Volumetric MRI also showed that there was no significant difference in the
volumes of calf muscles in AMSAN (142 ± 5 mm3) and control (143 ± 3 mm3) sera treated
animals (Fig. 5B). These observations suggest that anti-GM1 Abs in AMSAN serum did not
induce inhibition of motor nerve regeneration by the measures of motor reinnervation used
in this study.
Passive transfer of cholera toxin β subunit (CTB) impairs nerve repair in the PNS
We next examined the effects of CTB, a specific ligand of ganglioside GM1, to determine
whether other GM1 ligands have inhibitory effects on nerve repair. We found that CTB-
treated nerves had a significant increase in large diameter unmyelinated axons resembling
dystrophic sprouts in the S2 segment of the nerve compared to vehicle-treated controls
(Figure 6A&B). Electron microscopy confirmed that these large dystrophic axons remained
unmyelinated and were almost always associated with Schwann cells (Figure 6D).
Histograms of the axon calibers showed that the distribution of MFs was similar in both
CTB- and vehicle-treated mice but the distribution of unmyelinated fibers showed a
significant rightward shift due to dystrophic change in CTB-treated animals (Fig. 6E&F).
Dystrophic sprouts were restricted to the S2 (sciatic) segment and were not seen in S3
(tibial) segment of the CTβ-treated nerves. Morphometry showed that the total number of
regenerating myelinated fibers were significantly (p < 0.05) decreased in CTB-treated
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nerves at sciatic (1264 ± 86) and tibial (135 ± 5) levels (S2 and S3 segments, respectively)
compared to vehicle-treated controls (2309 ± 349 and 350 ± 23 in sciatic and tibial
segments, respectively).
Motor reinnervation was assessed in mice treated with CTB. We found that CMAP
amplitudes (recorded in hindpaws; Fig. 7) were significantly (p < 0.05) smaller in the CTB-
treated group (0.6 ± 0.25 mv) compared to controls (1.5 ± 0.3 mv).
Passive transfer of IgG anti-GM1 mAb does not impair axon regeneration
We then examined the effects of an IgG anti-GM1 mAb on nerve repair and found that this
mAb did not induce inhibition of axon regeneration in wild type mice at sciatic (2658 ± 97)
and tibial (656 ± 34) levels (S2 and S3 segments, respectively) compared to control IgG
treated animals (2723 ± 146 and 644 ± 42 in sciatic and tibial segments, respectively).
Determination of titer and affinity of anti-GM1 antibodies used for passive transfer
In order to examine factors that could influence anti-GM1 Ab-mediated impairment of axon
regeneration, we analyzed the titer of circulating anti-GM1 Abs in mice receiving GBS sera.
Table 1 shows that mice treated with patient sera have an antibody titer that range from
1/3200 to 1/12800 and animals treated with GM1-2b mAb had titers up to 1/409,600. We
found that affinity (IC50) for JHH-9 and 98-7 were 8×10−6M and 1×10−4M respectively
(Table 1). IC50 could not be determined for GM1-2b mAb with highest concentration tested
(1×10−4 M). These results indicate that the antibody affinity but not the titers correlate with
inhibition.
GM1 ligands have distinct patterns of binding to GM1-derivatives
Figure 8A shows the structures of the sialic-acid derivatives used in this study. The
structural requirements of GM1ligands were evaluated by examining their reactivities to
different derivatives of GM1 bearing chemical substitutions on the sialic acid (Fig. 8B). We
observed that modifications of the carboxyl group dramatically affect the reactivity of CTB
and GM1-2b and 98-7 Abs in contrast to the reactivity of JHH-9 Abs that was much less
affected. It is noteworthy that CTB and 98-7 react with one of the three derivatives targeting
the carboxyl group (GM1-alcohol and GM1-methylester, respectively) supporting the notion
that the interaction of the carboxyl group with these ligands is different. Modification of the
glycerol chain (GM1-7-aldehyde) abolished the reactivity of 98-7 and GM1-2b Abs and
CTB but did not affect the reactivity of JHH-9 Abs. Finally elimination of the N-acetyl
group dramatically reduced the reactivity of 98-7 Abs and CTB but did not affect the
binding of JHH-9 and GM1-2b Abs (Fig. 8B). In summary, the individual GM1 ligands used
in this study display unique structural requirements on the sialic acid of GM1 ganglioside.
Discussion
Our results show that passive transfer of sera and/or IgG fractions and affinity purified IgG
anti-GM1 Abs from two patients with GBS impaired axon regeneration/nerve repair in an
animal model. We found that these inhibitory effects could also be reproduced by CTB,
which is a specific ligand for ganglioside GM1. In contrast, a low affinity mAb GM1-2b did
not inhibit regeneration in wild type animals. These results indicate that ligand related
factors such as affinity and fine specificity are important determinants for antibody/ligand-
mediated inhibition of nerve repair. These results support the notion that patient IgG anti-
GM1 Abs can impair axon regeneration and modulate repair process in the peripheral
nerves.
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This study included a patient who had severe form of GBS with motor and sensory axon
involvement, IgG anti-GM1 Abs, and poor recovery (JHH-9). We show that these patient
derived IgG fractions and affinity purified IgG anti-GM1 Abs inhibit nerve repair. These
findings demonstrate that patient derived autoimmune Abs targeting GM1-like epitopes
inhibit nerve repair in a preclinical animal model. High titers of IgG anti-GM1 Abs have
been strongly associated with GBS particularly with axonal forms of this disorder (Yuki et
al., 1990) and with poor prognosis and/or incomplete recovery (Ilyas et al., 1992;Gregson et
al., 1993;Simone et al., 1993;Kuwabara et al., 1998b;Kuwabara et al., 1998a;Jacobs et al.,
1996;Carpo et al., 1999;Bech et al., 1997;Press et al., 2001;Hadden et al., 2001;Annunziata
et al., 2003;Koga et al., 2003). The current study provides one potential explanation for poor
recovery and associated impairment in nerve repair in GBS patients with high titers of anti-
GM1 Abs.
Comparative studies with Abs and CTB besides providing ‘proof of concept’ also provide
important insights into the properties of the ligands that determine the selectivity of the fiber
type affected. We observed preferential inhibition of sensory fiber regeneration with GBS
sera whereas CTB induced inhibition of motor and likely sensory fibers. The inhibitory
effects of the JHH-9 and CTB correlate with the nerve fiber binding patterns of these
ligands. In this study we show that JHH-9 Abs preferentially stain sensory fibers and inhibit
regeneration of sensory fibers. We have reported that CTB binds to both motor and sensory
fibers (Sheikh et al., 1999a), which is consistent with the CTB-mediated inhibition of motor
and sensory nerve fibers in this study. GM1-2b mAb did not induce inhibitory effects likely
due to its affinity-avidity (see below) despite its reported binding to motor and sensory nerve
fibers (Gong et al., 2002). The immunocytochemical studies (which require affinity purified
anti-GM1 Abs because normal human serum can have anti-neurofilament Abs and axonal
binding (Stefansson et al., 1985)) with 98-7 Abs could not be performed because of limited
quantity of this serum was available. Fine specificity experiments indicate that GM1 ligands
used in this study have distinct reactivities to GM1-derivatives and this could be one factor
that influences selective nerve fiber/target recognition, as was suggested previously
(O'Hanlon et al., 1996;Lopez et al., 2008). Besides fine specificity of the Abs, accessibility
of glycolipid antigens to Abs is also very important. Willison’s group in Glasgow has
recently demonstrated that just a very small fraction of all the GM1 epitopes recognized by
Abs may be accessible for binding on mouse motor nerves under physiological conditions
(Greenshields et al., 2009) providing another explanation for selective sensory fiber
involvement with passive transfer of anti-GM1 Abs in GBS sera in our animal studies.
Further, CTB has been shown to cross-link cell surface GM1 and induce calcium influx via
L-type voltage gated calcium channels or TRPC5 channels (Buckley et al., 1995;Wang et
al., 2009), whereas IgG anti-GM1 Abs in one study did not induce calcium influx
presumably due to binding without cross-linking of GM1 (Quattrini et al., 2001). Whether
GM1 cross-linking by CTB and engagement without cross-linking by IgG anti-GM1 Abs
relate to differences in inhibitory effects is not possible to address in these animal studies
and requires separate examination of this issue.
Our findings indicate that beside fine specificity of Abs affinity-avidity of the ligands may
also relevant to the inhibition of nerve fiber regeneration. CTB is an oligomeric protein
complex ring containing five β-subunits, each of them able to bind GM1 ganglioside. The
high affinity interaction of each individual subunit with GM1 plus the pentameric nature of
the β-subunit makes CTB one of the most powerful ligands for GM1 (Schon and Freire,
1989;MacKenzie et al., 1997). On the other hand, the affinity of IgG anti-GM1 Abs from
GBS sera and experimental mAb used in this study is diverse. For instance while serum
JHH-9 has an affinity of 8×10−6M comparable to single β-subunit of CTβ (1×10−6 M
(Schon and Freire, 1989)) and serum 98-7 showed relatively lower affinity anti-GM1 Abs
(10−4M). GM1-2b mAb with the lowest affinity (>10−4M) did not produce inhibition.
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Noticeably, the inhibition with human anti-GM1 Abs (low to moderate affinity) is not that
different from that of highest affinity ligand CTB (Fig. 1 and 6). The major explanation for
this is most probably due to differences in the kinetics and distribution of CTB and Abs in
the injured nerves. It is established that CTB is retrogradely transported by intact or injured
nerve fibers after systemic or local intraneural administration (Alisky et al., 2002;Tong et
al., 1999;Santha and Jancso, 2003). In our animal model, it is very likely that CTB is
internalized and retrogradely transported by injured axons, thereby, terminating CTB’s
interaction with surface glycolipids of injured axonal tips. Further, we have recently found
that expression of Fc-gamma (Fcγ) receptors on injured Schwann cells is a prerequisite for
anti-ganglioside antibody-mediated inhibition of axon regeneration (Sheikh et al., 2009)
suggesting that these receptors anchor IgG antibodies via their Fc fragments for interaction
with adjacent regenerating axons. This Fc-Fcγ binding is likely to influence the operative
affinity/avidity of antibody-antigen interactions and also prevent internalization of the Abs
thus enhancing their effective half-life and pathogenicity in the injured nerves.
The current study directly links patient-derived IgG poly/oligoclonal anti-GM1 Abs to
inhibition of axon regeneration and extends our previous findings showing that a GD1a/
GT1b-reactive mAb induced severe inhibition of axon regeneration in mice (Lehmann et al.,
2007). The GD1a/GT1b-reactive mAb induced more inhibition of both sensory and motor
nerve fibers compared to the GBS sera or CTB, however, the two studies are not directly
comparable because the specificity of anti-ganglioside Abs, origin of Abs/ligands, and dose
of anti-ganglioside Abs/ligands used in these studies are very different. Our results are
consistent with previous findings indicating that Abs directed against GM1 or other
gangliosides can inhibit regeneration in non-mammalian neurons (Spirman et al.,
1982;Schwartz and Spirman, 1982;Sparrow et al., 1984;Spoerri et al., 1988); current study
extends this finding to mammalian neurons.
There are two clinical studies that have noted that not all patients with GM1 Abs and GBS
have adverse outcome or poor recovery (Vriesendorp et al., 1995;Enders et al., 1993). The
pathogenecity of anti-ganglioside antibody-mediated nerve injury is a complex
multifactorial issue (Sheikh and Zhang, 2010). Neurobiological factors such as extent and
site of axonal injury and age-related regenerative capacity of the host (Black and Lasek,
1979) are important factors on the one hand. On the other hand are immunological factors
related to antibody-antigen characteristics such as antibody affinity and fine specificity
(highlighted in this study), antigen density (Goodfellow et al., 2005), isotype of the antibody
which affects the half-life of circulating Abs (Koga et al., 2003), and as yet other undefined
factors. Serological studies primarily defining the specificity of anti-ganglioside Abs in
patients with GBS and correlating this with clinical recovery are likely to have low
predictability because solid phase assays commonly used to determine the presence of Abs
do not provide any information about these immunological factors related to antibody-
mediated adverse effects on nerve repair (Sheikh and Zhang, 2010).
Our findings have important implications for neural repair in autoimmune neurological
disorders. We show that circulating immune effectors can access injured nerves and
adversely affect nerve repair. This is particularly relevant to immune neuropathies such as
GBS and chronic inflammatory demyelinating polyneuropathy in which recovery relates to
the extent of axon injury (Asbury et al., 1969;Brown and Feasby, 1984;Feasby et al.,
1986;Bouchard et al., 1999). Recovery in these situations require axon regeneration and
target reinnervation and the presence of autoantibodies against gangliosides can foil the
injured axons attempt to regenerate. These observations raise the possibility that immune
effectors (including Abs) may also impair the neural repair in CNS disorders such as
multiple sclerosis in which autoantibodies including those against glycolipids are
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increasingly recognized (Cross et al., 2001;Kanter et al., 2006). Modulation of CNS repair
by immune effectors is an important issue that requires further studies.
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Figure 1.
GBS patient sera-mediated inhibition of peripheral nerve repair. A, Schematic diagram
showing the site of nerve crush and its relationship to different nerve segments (S1–S3), as
outlined in the text. B&C, micrographs from control and GBS sera-treated S3 nerve
segments showing fewer regenerating fibers in GBS sera-treated nerve (scale bar = 25 μm ).
D&E, Significant decrease in number of regenerating axons at sciatic (S2; D) and tibial (S3;
E) nerve levels in GBS (AMSAN and AMAN)-treated nerves compared to control serum-
treated nerves. *p<0.05.
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Figure 2.
IgG fractions and affinity-purified IgG anti-GM1 antibodies from AMSAN serum inhibit
nerve repair. A&B, Significant decrease in number of regenerating axons at sciatic (S2; A)
and tibial (S3; B) nerve levels in animals treated with IgG fractions or IgG anti-GM1
antibodies compared to control animals treated with IVIg. *p<0.05.
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Figure 3.
Human IgG accumulates in injured nerves. Compared to control nerves (A) there is a
significant increase in IgG accumulation in AMSAN sera-treated nerves (B). Scale bar = 1
mm.
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Figure 4.
AMSAN serum inhibits regeneration in sensory nerves. Representative micrographs
showing regenerating nerve fibers in control serum-treated nerve (A) compared to JHH-9
serum- treated nerve (B), which hardly has any regenerating fibers. Scale bar = 20 μm. C,
Affinity purified IgG anti-GM1 antibodies from AMSAN serum preferentially bind to dorsal
roots (red, left panel). IB4 staining (green) on the corresponding field is shown in the right
panel to delineate ventral (VR) and dorsal roots (DR). Scale bar = 50 μm.
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Figure 5.
AMSAN serum does not affect motor nerve regeneration. A, Representative micrographs
showing comparable evoked motor amplitudes in AMSAN- and control serum-treated
animals. B, Control- and AMSAN serum- treated nerves do not show significant differences
in calf muscle volumes determined by MRI.
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Figure 6.
Cholera toxin B-mediated inhibition of peripheral nerve repair. A–D, Light (scale bar = 2
μm) (A&B) and electron (scale bar = 2 μm) (C&D) micrographs of sciatic nerve S2
segments. A–B, Many regenerating fibers are present in both vehicle (A)- and CTB (B)-
treated nerves. C–D, Normally myelinating fibers are present in the vehicle-treated nerves
(C) whereas large dystrophic-appearing axons without myelination are commonly present in
the CTB-treated nerves (D) at the sciatic level (S2). E&F, Histograms showing distribution
of myelinated (E) and unmyelinated dystrophic fibers (F) in vehicle (control)- and CTB-
treated nerves at sciatic (S2) level; a marked rightward shift in the distribution of
unmyelinated dystrophic axons is seen with CTB treatment (F).
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Figure 7.
Motor reinnervation is reduced in CTB-treated animals. A&B, Representative tracings
recorded in hindpaws of mice showing decreased CMAP amplitudes in CTB-treated mice
(B) compared to vehicle-treated controls (A).
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Figure 8.
(A) GM1 derivatives. Positions of the chemical substitutions made on the N-
acetylneuraminic acid residue of GM1 according to description under Materials and
Methods. (B) Effect of sialic acid modifications on binding of GM1 ligands. Ligand
reactivity to GM1 and GM1-derivatives was analyzed by solid phase assays and quantified
as described under Materials and Methods.
Lopez et al. Page 21
J Neurosci. Author manuscript; available in PMC 2011 February 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Lopez et al. Page 22
Table 1
Circulating titers and affinity (IC50) of patient sera and anti-GM1 mAb
GBS patient/mAb JHH-9 98-7 IgG GM1-2b
Circulating Ab titer 6,400–12,800 3,200 204,800–409,600
IC50 (oligo-GM1) 8×10−6M 1×10−4M >1×10−4M
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